Contingent Value Rights Substack

Home
Archive
About

June 2025

Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences
Concentra Found another Zombie biotech.
 • 
Contingent Value Rights
1
Supernus Pharmaceuticals is set to acquire Sage Therapeutics
Please read the SEC documents regarding this current security and understand that I do own of these shares.
 • 
Contingent Value Rights
Concentra Biosciences/Tang Capital Management acquires Kronos Bio
Concentra keeps coming back to the well for more water. 2 years until expiration.
 • 
Contingent Value Rights
Republic is acquiring INX
18 months until expiration
 • 
Contingent Value Rights
Pan American Silver Corp. completed its acquisition of Tahoe Resources Inc.
Ongoing CVR that trades - The CVRs had a term of ten years.
 • 
Contingent Value Rights
Novartis completes acquisition of Regulus Therapeutics
Novartis acquires Regulus for $7.00 per share in cash, with potential to receive an additional $7.00 per share in cash
 • 
Contingent Value Rights
2
Sanofi to acquire Blueprint Medicines
Sanofi will pay $129.00 per share in cash and one CVR which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR
 • 
Contingent Value Rights
1
Questions about CVRs
https://www.ainvest.com/news/contingent-rights-red-flag-biotech-tech-mergers-2506/
 • 
Contingent Value Rights

March 2025

© 2025 Contingent Value Rights
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture